Abiomed Announces Q2 FY 2016 Revenue of $76.4 Million, Up

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Abiomed Announces Q2 FY 2016 Revenue of $76.4 Million, Up 47% Over Prior Year

DANVERS, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD ), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2016 revenue of $76.4 million, an increase of 47% compared to revenue of $51.9 million for the same period of fiscal 2015. Second quarter fiscal 2016 GAAP net income was $7.7 million or $0.17 per diluted share, an increase of 103% and 89% respectively, compared to GAAP net income of $3.8 million or $0.09 per diluted share for the prior year period.

Financial and operating highlights during the second quarter of fiscal 2016 include:

  • Fiscal second quarter worldwide Impella® heart pump revenue totaled $71.7 million, an increase of 53% compared to revenue of $46.9 million during the same period of the prior fiscal year.  U.S. revenue grew 59% to $66.7 million from $42.0 million in the prior fiscal year with patient usage up 48%.   
  • The installed base for Impella 2.5 grew by an additional 27 hospitals, bringing the installed customer base to 1,000 sites.  As part of Abiomed's continued Impella CP® heart pump launch, 45 new hospitals purchased Impella CP, bringing the total number of Impella CP U.S. sites to 739.   
  • The Impella RP® heart pump installed base has a goal of 60 sites for the entire fiscal year. As of the end of the second quarter, the Company is ahead of schedule, with an additional 31 hospitals that made initial purchases of the Impella RP during the quarter, bringing the total number to 54  Impella RP U.S. sites.  
  • Gross margin for fiscal second quarter 2016 was 84.1% compared to 81.5% in the second quarter of fiscal 2015.   
  • Income from operations for the second quarter of fiscal 2016 was $12.8 million, or 16.8% of revenue, compared to $4.2 million, or 8.0% of revenue in the prior year period.  
  • The Company generated $19 million in cash, cash equivalents and marketable securities, totaling $175.5 million as of September 30, 2015, compared to $156.4 million at June 30, 2015. The Company continues to have no debt.  
  • At its annual Investor Day on August 11, Abiomed outlined its long-term growth strategy and five-year vision for revenues and demonstrated future products in development, which can be accessed via webcast here: http://edge.media-server.com/m/p/ckvn5o7f . The future products, which were also recently displayed at the TCT 2015 conference, included:  
    • The Impella ECP™ (Expandable Cardiac Power) heart pump on a complete 9 Fr Impella catheter and pump;
    • The Next Generation Impella CP with an increased flow of 4.5 liters/minute and smart sensor technology;
    • The Impella 5.5, which can be implanted via axillary (without a sternotomy), is designed with a 19 Fr pump on a 9 Fr catheter for months of flow of 5.5 liters per minute and patient ambulation;
    • The longer term Impella BTR™ (Bridge to Recovery) heart pump, which can also be implanted via axillary (without a sternotomy), is designed to provide up to a year of 5.5 plus flow driven by a wearable driver.  
  • The Company also announced the submission of its U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplements in August. The supplements are requesting approval for the Impella family of heart pumps (Impella 2.5, Impella CP and Impella 5.0/LD). The submissions are requesting approval for a set of indications related to the use of the Impella devices in patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. A request for a longer duration of support was also included.  
  • A key clinical paper titled, “Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience,” was published in the American Heart Journal during the second quarter. The paper, authored by Mauricio Cohen et al., analyzed the results of high risk PCI (percutaneous coronary intervention) patients in the U.S. Impella (now cVAD™) Registry and determined that real-world clinical outcomes with the Impella 2.5 appeared to be favorable and consistent compared with the randomized PROTECT II trial.  
  • Seth Bilazarian, MD, was announced as the new Vice President of Interventional Cardiology Programs at Abiomed on October 8.  
  • At the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific sessions in October, there were over 25 Impella heart pump presentations, 3 Protected PCI symposia and 5 live Impella heart pump cases.

“We have had an exciting start to fiscal year 2016 with first half revenue growth of 49% and establishment of Protected PCI™ as a new indication. As evidenced by our patient growth and awareness at TCT, Protected PCI has been validated by physicians that treat higher risk patients requiring percutaneous hemodynamic support in the cath lab,” said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. “We are confident that in the years ahead, Abiomed will deliver strong growth, support new indications and countries, and launch new best in class products. As always, Abiomed is committed to meaningfully impacting the lives of our patients and helping our physicians improve outcomes.”

FISCAL YEAR 2016 OUTLOOK The Company is increasing its fiscal year 2016 guidance for total revenue to be in the range of $305 million to $315 million, up from $300 million to $310 million, representing an increase in revenue of 32% to 37% from the prior year.

The Company is updating its fiscal year guidance for GAAP operating margin to be in the range of 15% to 17%, from the previous guidance range of 14% to 16%.

CONFERENCE CALL The Company will release financial results for the second quarter of fiscal 2016. The Company will host a conference call to discuss the results on Thursday, October 29, 2015, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538.  A replay of this conference call will be available beginning at 11 a.m. EDT October 29, 2015 through 11:59 p.m. EDT on October 31, 2015. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 55643535.

The ABIOMED logo, ABIOMED, Impella, Impella RP and Impella CP are registered trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries.  Impella ECP, Impella BTR, Protected PCI, Recovering Hearts. Saving lives and cVAD are trademarks of Abiomed, Inc..

ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit:  www.abiomed.com

FORWARD-LOOKING STATEMENTS This release includes forward-looking statements.  These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning.  These forward-looking statements address various matters including, the development of Abiomed's existing and new products, the Company's progress toward commercial growth, the Company’s guidance for fiscal 2016 revenue and GAAP operating margins and future opportunities. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.  Applicable risks and uncertainties include, among others, uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and the risks identified under the heading “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended March 31, 2015 and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, each filed with the Securities and Exchange Commission, as well as other information the Company files with the SEC.  We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.  You are encouraged to read our filings with the SEC, available at www.sec.gov , for a discussion of these and other risks and uncertainties.  The forward-looking statements in this press release speak only as of the date of this release and the Company undertakes no obligation to update or revise any of these statements.  Our business is subject to substantial risks and uncertainties, including those referenced above.  Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share data)
         
    September 30, 2015   March 31, 2015
         
ASSETS        
Current assets:        
Cash and cash equivalents $   54,421     $   22,401  
Short-term marketable securities     121,087         109,557  
Accounts receivable, net      37,119         31,828  
Inventories      23,032         16,774  
Prepaid expenses and other current assets     4,030         4,479  
Deferred tax assets, net     25,715         35,100  
Total current assets     265,404         220,139  
Long-term marketable securities   —       13,996  
Property and equipment, net     11,420         9,127  
Goodwill       32,676         31,534  
In-process research and development     15,243         14,711  
Long-term deferred tax assets, net     44,240         45,206  
Other assets     4,423         3,654  
Total assets $   373,406     $   338,367  
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:      
Accounts payable $   8,788     $   10,389  
Accrued expenses     18,861         21,894  
Deferred revenue     6,803         7,036  
Total current liabilities     34,452         39,319  
Other long-term liabilities     217         183  
Contingent consideration     6,817         6,510  
Long-term deferred tax liabilities     824         795  
Total liabilities     42,310         46,807  
Commitments and contingencies    
Stockholders' equity:      
Class B Preferred Stock, $.01 par value   —     —
Authorized - 1,000,000 shares; Issued and outstanding - none
Common stock, $.01 par value     424         413  
Authorized - 100,000,000 shares; Issued - 43,756,550 shares at September 30, 2015   and 42,618,717 shares at March 31, 2015;        
Outstanding - 42,417,469 shares at September 30, 2015 and 41,335,773   shares at March 31, 2015        
Additional paid in capital     489,463         465,046  
Accumulated deficit     (120,628 )       (137,222 )
Treasury stock at cost - 1,339,081 shares at September 30, 2015 and 1,282,944   shares at March 31, 2015       (23,157 )       (19,347 )
Accumulated other comprehensive loss     (15,006 )       (17,330 )
Total stockholders' equity     331,096         291,560  
Total liabilities and stockholders' equity $   373,406     $   338,367  

 

Abiomed, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share data)
 
    For the Three Months Ended September 30,   For the Six Months Ended September 30,
    2015   2014   2015   2014
Revenue:                        
Product revenue $   76,354   $     51,774     $   149,780   $     100,434  
Funded research and development     5         164         11         315  
        76,359         51,938         149,791         100,749  
Costs and expenses:                      
Cost of product revenue    12,144         9,612         23,012         19,301  
Research and development    11,569         8,693         21,779         17,755  
Selling, general and administrative      39,829         29,455         77,152         61,053  
        63,542         47,760         121,943         98,109  
Income from operations     12,817         4,178         27,848         2,640  
Other income (loss):                      
Investment income, net   62         36         125         80  
Other income (loss), net     87         (39 )       140         (28 )
        149         (3 )       265         52  
Income before income taxes   12,966         4,175         28,113         2,692  
Income tax provision     5,231         336         11,519         562  
Net income $   7,735   $     3,839     $   16,594   $     2,130  
                         
Basic net income per share $   0.18   $     0.09     $   0.40   $     0.05  
Basic weighted average shares outstanding   42,228         40,448         41,963         40,256  
                         
Diluted net income per share $   0.17   $     0.09     $   0.37   $     0.05  
Diluted weighted average shares outstanding   44,922         42,239         44,778         42,069  

For further information please contact:   Ingrid Goldberg, Director, Investor Relations 978-646-1590 ir@abiomed.com Aimee Genzler Director, Corporate Communications 978-646-1553 agenzler@abiomed.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 92

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 52

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 28

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 89

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 81

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 43

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 67

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading

Top 5 Most Recently Viewed Articles

PAPZIMEOS Emerges as the Go-To Treatment for RRP Patients

Updated Category News Views 104

PAPZIMEOS: A Promising New Standard for RRP Therapy PAPZIMEOS (zopapogene imadenovec) has gained recognition as an innovative treatment for adults suffering from recurrent respiratory papillomatosis (RRP). This breakthrough comes following the publication of a consensus paper authored by 16 leading experts in the field. Sponsored by the Recurrent Respiratory...

Continue Reading
Ollie's Bargain Outlet Reports Encouraging Q2 Results

Updated Category News Views 159

Ollie's Bargain Outlet Achieves Strong Q2 Performance Ollie's Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) has made headlines recently as its shares experience fluctuations in the market. The company revealed impressive second-quarter adjusted earnings per share of 99 cents, surpassing analyst expectations of 94 cents. The quarterly sales reached $679.556 million, marking...

Continue Reading
Fivecast Introduces Groundbreaking Discovery Solution for OSINT

Updated Category News Views 184

Fivecast Unveils Discovery Solution to Combat Global Threats In today's rapidly evolving landscape of global threats, Fivecast, a prominent provider of advanced open-source intelligence (OSINT) solutions, has rolled out an innovative Discovery solution designed to assist analysts and investigators in both government and corporate settings. By elevating the speed and...

Continue Reading
Zen Technologies USA Advances Military Training with AI Simulations

Updated Category News Views 224

Zen Technologies USA Showcases Cutting-Edge AI Simulations Zen Technologies USA is set to revolutionize military training capabilities with its next-generation AI-enabled live and virtual simulation solutions. By enabling high-fidelity training for ground and naval forces, these innovations aim to accelerate the readiness of military units while significantly reducing...

Continue Reading
Sectra and Siemens Healthineers Transform Radiology Workflows

Updated Category News Views 494

Revolutionizing Radiology with Innovative Integrations International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Siemens Healthineers AG have formed a pivotal collaboration aimed at enhancing diagnostic capabilities in the radiology field. This initiative seeks to improve patient care by enabling seamless access to advanced imaging technologies....

Continue Reading